DESCRIPTION
The mission of Medical Countermeasure Systems (MCS) — Biological Defense Therapeutics (BDTX) is to provide U.S. military forces and the nation safe, effective, innovative and affordable therapeutic solutions to counter traditional, emerging and engineered biological threats.
The BDTX portfolio consists of:
Antiviral Therapeutic (AVTX), which provides therapeutic or protection against the effects of Hemorrhagic Fever Virus (HFV) families (Filoviridae and Bunyaviridae) and Encephalitic Alphaviruses (Togaviridae), thus sustaining the warfighter to complete the mission. HFV countermeasures will mitigate the threat of illness or death, as well as lessen issues with performance degradation resulting from exposure to hemorrhagic fever viruses (Ebola and Marburg). Due to the severity of these diseases, HFV therapeutics will be administered to exposed warfighters while under direct medical observation.
Countermeasures for Multi-Drug Resistance-Bacterial (CMDR-B) develop post-exposure medical countermeasures to treat service members exposed to bacterial threats engineered to defeat current antimicrobial countermeasures. CMDR-B therapeutics will be administered to exposed warfighters while under direct medical observation.
BENEFIT TO THE SOLDIER
MCS BDTX provides therapeutic solutions to counter traditional, emerging and engineered biological threats.
SPECIFICATIONS
System attributes established in requirements documentation
PROGRAM STATUS
FY16-FY18:
- AVTX:
Stood up Joint Mobile Emerging Disease Intervention Clinical Capability to execute human clinical research of experimental therapeutics in an emerging infectious disease outbreak setting
Initiation of second site NHP pivotal efficacy study design - CMDR-B:
Other Transaction Authority Award Medical Countermeasures for multidrug resistant bacteria
PROJECTED ACTIVITIES
AVTX:
- FY19: Natural History Study Results
- FY22: Milestone C
CMDR-B:
- FY19:
- Market Research analysis
- Prototype Testing analysis results
- Milestone B